Regulatory and clinical outcomes of priority-reviewed innovative cancer drugs in China between 2015 and 2024: an observational study by Qi Li, Nan Peng, Linfeng Jiang, Huting Zhou, Pengcheng Liu, Haijing Guan, Dongning Yao

Subjects: “…Accelerated approval…”
Get full text

Cancer Drugs Approved Based on Surrogate Endpoint: A Retrospective Observational Study in the United States and China by Ting Zhu, Jinjia Zhong, Yafang Huang

Subjects: “…accelerated approval…”
Get full text

Strength of clinical evidence supporting the United States Food and Drug Administration Accelerated Approvals from 2015 to 2022 by Xiaofang Zhang, Carl C. Peck, Yaning Wang, Thomas D. Szucs, Wan Sun, Xue Bai, Siyu Chen, Fengzhi Wang, Yangfeng Wu

Subjects: “…Accelerated approval…”
Get full text

Marketing Authorisation Based on Incomplete Clinical Data: International Experience and Prospects by D. V. Goryachev, N. E. Uvarova, G. V. Shukshina

Subjects: Get full text

Regulatory landscape of accelerated approval pathways for medical devices in the United States and the European Union by Tanvi Gupte, Tushar Nitave, Tushar Nitave, Jogarao Gobburu

Subjects: Get full text